Drugs.com: Effect of cancer treatment on COVID-19 mortality
A UC study sheds light on death rates as they relate to patients with cancer and COVID-19
Cancer patients treated one to three months prior to COVID-19 diagnosis and those treated with chemoimmunotherapy have the highest 30-day mortality, according to a study presented at the annual meeting of the European Society for Medical Oncology, held virtually from Sept. 19 to 21.
Lead author Trisha Wise-Draper, MD, PhD, associate professor of medicine, UC Health oncologist and member of the UC Cancer Center, and colleagues examined outcomes related to systemic cancer treatment within one year of laboratory-confirmed severe acute respiratory syndrome coronavirus 2 infection.
Read the full Drugs.com/HealthDay News story.
Featured photo courtesy of the National Cancer Institute.
Next Lives Here
The University of Cincinnati is classified as a Research 1 institution by the Carnegie Commission and is ranked in the National Science Foundation's Top-35 public research universities. UC's graduate students and faculty investigate problems and innovate solutions with real-world impact. Next Lives Here.
Related Stories
UC studies: Silent mutations, tumor microenvironment may be therapeutic targets
April 17, 2026
University of Cincinnati Cancer Center researchers will present abstracts at the American Association for Cancer Research Annual Meeting 2026 April 17 to 22 in San Diego.
New UC Blue Ash business officer is a familiar face on campus
April 17, 2026
Lacey McCarthy will bring her skills, expertise and more than 20 years of experience in budget and financing to her new role as business officer for the University of Cincinnati Blue Ash College.
UC experts present neurology research at national conference
April 17, 2026
University of Cincinnati researchers will present abstracts at the 2026 American Academy of Neurology Annual Meeting April 18 to 22 in Chicago.